Curaleaf thanks former chief financial officer (CFO) and welcomes new appointment of Ranjan Kalia.
Kalia joined international provider of cannabis products Curaleaf Holdings, Inc. as CFO on 19 July. He succeeded Michael Carlotti who has stepped down for medical reasons.
Commenting on the appointment, Curaleaf CFO, Kalia, said: “I am truly honoured to be joining the Curaleaf team at this exciting time in the company’s evolution. As Curaleaf has established itself as the global pure play cannabis leader, the company remains in the very early innings of its long-term potential development in this dynamic and fast growing industry.
“I look forward to partnering with the entire Curaleaf team to continue executing on its track record for financial performance, strong balance sheet and robust engagement with the financial community.”
Kalia will bring a wealth of expertise to Curaleaf after having served as executive vice president and chief financial officer of Virtusa Corp, a global provider of digital strategy, and extensive experience and knowledge across corporate tax regulations, US SEC regulations and Sarbanes Oxley compliance requirements.
He has also spent eight years with EMC Corporation serving in various roles including vice president of finance and chief financial officer – Asia-Pacific region, and has held senior financial controller and audit positions at GE Capital, Pepsi Cola Co., and Pricewaterhouse Coopers.
Boris Jordan, Executive Chairman of the Board of Curaleaf, commented: “On behalf of the Board of Directors and the executive leadership team I want to personally thank Mike for his tremendous commitment and contributions to Curaleaf. During Mike’s tenure as Chief Financial Officer he delivered exceptional financial performance management while ensuring the Company maintained its commitment to a strong balance sheet to help drive our business and meet our goals. Mike played an important role in setting the foundation for our future success; moreover, he’s an exceptional professional and friend. We wish him all the best for a prompt and full recovery.”
Joseph Bayern, Chief Executive Officer of Curaleaf, commented: ”I am pleased to welcome Ranjan to the Curaleaf executive leadership team. With over thirty years of experience in executive finance positions at complex multinational companies, Ranjan brings a wealth of expertise which will be instrumental in helping fuel our continued growth. He’s joining us at a very exciting time for our company and I look forward to working with him.”
Cellular Goods makes changes to board, welcoming author as NED
The company is welcoming new non-executive directors (NED) to the board.
UK-based Cellular Goods has appointed author Gill Whitty-Collins and marketing executive Misha Sher as NEDs.
The pair have been appointed as NEDs in a shake up of the company’s board. Whitty-Collins succeeds David Gardner, who is leaving due to time commitments at his other business interests, and Sher succeeds Ross Connolly.
NED Darcy Taylor will also assume the role of non-executive chairman, succeeding Peter Wall. Wall is stepping down as chairman in order to devote more time to his existing executive roles and increased commitments but will remain a NED of the Company.
Non-executive chairman of Cellular Goods, Darcy Taylor, commented: “I’m delighted to accept the baton from Peter as Cellular Goods embarks on the next phase of its development. On behalf of the Board, I would like to thank David and Ross for their contributions and wish them all the best in their future endeavours.
“I would also like to welcome Gill and Misha. They have an impressive track record, and their counsel will enhance the Board’s strategic oversight of the Company. The Board looks forward to working closely with the senior executive team under our chief executive, Anna Chokina, to drive the Company’s growth and deliver long term value for shareholders.”
Whitty-Collins joined Cellular Goods as a leader in business, brand-building, equality and diversity with more than 25 years’ senior leadership experience at Procter & Gamble (P&G), where she led global brands such as Olay, Always and Pantene, latterly as Senior Vice President for the beauty care business for Europe, India, Middle East & Africa.
She is also the author of ‘Why Men Win at Work… and how we can make inequality history’ with extensive experience and knowledge of the gender inequality issue and how to address it.
Sher is a senior marketing executive with over two decades of experience working with leading brands, rights holders and talent. Mr Sher spearheaded the growth of an award-winning sports, entertainment and culture business unit at MediaCom, one of the world’s largest media and communications agencies.
He has worked with some of the world’s largest brands including eBay, Uber, Coca-Cola, P&G, American Airlines, Apple and Toyota on investment in leading cultural properties. He currently serves as NED at the European Sponsorship Association.
Former Clinton administration advisor joins cannabis board
FoliuMed has announced a new appointment to its advisory board.
FoliuMed has announced the appointment of former advisor to the Clinton administration Howard Glicken to its advisory board.
Glicken will be Brigit a waltz of experience to the FoliuMed advisory board. Having served as a private sector advisor to the Clinton administration on Latin American affairs, Glicken was also the President´s private sector delegate to the Inaugurations of Presidents of Argentina, Uruguay, Peru and Ecuador.
Additionally, he testified before the US Congress on the Free Trade Area of the Americas and is a member of the US/Brazil Business Development Council.
In his role at FoliuMed, Glicken will expand institutional and business relationships in the Americas.
Glicken commented: “What impresses me most about FoliuMed is its leadership team led by founder Oliver Zugel.
“Since 2018 it has built the company with its own capital and is selling innovative products in eight countries. By sourcing cannabis ingredients from its farm in Colombia, it offers German pharma-quality at affordable prices.”
Oliver Zugel, founder of FoliuMed, a medical cannabis company with manufacturing and R&D in Germany and cultivation in South America, commented: “We are honoured to be able to count on Howard’s advice and mentorship, including his views on the upcoming German adult-use regulations.
“His over 40 years of experience in business and politics and background as a successful entrepreneur make him a valued member of our advisory board.”
During his political career, Glicken also has been national vice chairman of finance of the Democratic Party, a member of the national finance board of directors and a managing trustee of the party.
He also was state finance chair for Al Gore for President 1988, state finance chair for Senator Bob Kerrey for President in 1992, state co-finance chair for President Clinton and a trustee of the Vice President’s Residence Foundation.
Former GSK director joins cannabis company
Bill Purves has joined Brains Bioceutical as chief commercial officer.
Former GlaxoSmithKline executive director, Bill Purves, has joined global manufacturer of naturally-sourced active pharmaceutical ingredients, Brains Bioceutical, as its chief commercial officer.
Bill Purves will now be at the forefront of a new frontier in the research and development of cannabinoids for health and wellness sectors, says Brains Bioceutical.
Purves will be responsible for the company’s global sales and marketing operations, and the company says he will diversify its product offerings while playing a pivotal role in the evolution of cannabinoid science.
“After many years in the pharmaceutical industry, combined with time spent working in the cannabis industry, I have the utmost confidence in what we’re doing at Brains Bioceutical,” commented Purves.
“I’m excited to see the potential of cannabinoid pharmaceuticals come to life and the positive impacts this will have in pharmacological advancements.
“We are looking at the future of disease treatment and prevention here at Brains Bioceutical.”
Ricky Brar, CEO of Brains Bioceutical, commented: “Brains is in a unique position to rapidly capitalise on our industry-leading Cannabinoids API via the pharmaceutical industry, and now with Novel Foods Validation in both the EU and UK, Brains will emerge as the industry leader in nutraceuticals.
“Bill Purves, in his role as chief commercial officer of Brains Bio, is ideally positioned to lead these categories, within an emerging global leader.
“His experience will be an asset as we continue to innovate and lead in the cannabinoid space.”
With experience in the pharmaceutical and phytocannabinoid industries, Purves will lead Brains Bio’s business development strategy, explore new revenue streams and solidify relationships with existing and prospective customers.
Starting his pharmaceutical career with GlaxoSmithKline in 1994 as senior financial analyst, he then moved into the role of chief financial officer of the company’s business operations in Sub-Saharan Africa.
Five years later, Purves was promoted to executive director of GlaxoSmithKline’s international business development, providing strategic planning and market development support across the company’s international business unit.
In 2007, where Purves was responsible for establishing the Iroko Pharmaceuticals’ global sales and distribution networks for branded generic and specialty prescription products. He later co-founded and acted as managing member of Windhoek Healthcare, a US-based healthcare investment firm, which launched three specialty pharmaceutical companies.
Purves entered the medical cannabis space in 2018 when he was hired by Jacana, a Jamaican medical cannabis company, as its CCO and CFO, where he helped transform the startup into a fully, vertically integrated medical cannabis company with business arms that included research and development, cultivation, production and extraction.
- New agreement to fund Phase II trials for cannabis glaucoma treatment
- Discover Europe’s first registered cannabis seedbank
- What can Uruguay teach the UK about cannabis policy?
- Flora Growth steps up international growth strategy with opening of offices in London
- Roundup of Q1 2022 financial results in the UK medical cannabis space